How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment

Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S8-S11. doi: 10.1016/S2152-2650(20)30443-2.

¹ Hospital for Sick Children and University of Toronto, 555 University Ave, Toronto, ON, M5G 1X8, Canada.
² Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, 3501 Civic Center Blvd, Philadelphia, PA, 19104, United States.
³ Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, OH, 45229, United States.
⁴ Baylor College of Medicine, Texas Children's Hospital, 1102 Bates Street, Houston, TX, 77030, United States.
⁵ University of Chicago Comer Children's Hospital, 5841 S Maryland Ave, Chicago, IL, 60637, United States. Electronic address: jmcneer@peds.bsd.uchicago.edu.

No abstract available

Keywords: B-ALL; blinatumomab; children; inotuzumab ozogamicin; tisagenlecleucel.

MeSH terms